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In spite of the clinical need, there is a major gap in rapid diagnostics for identification and 2 
quantitation of E. coli and other pathogens, also regarded as the biggest bottleneck in the fight 3 
against the spread of antimicrobial resistant bacterial strains. This study reports for the first 4 
time an optical, smartphone-based microfluidic fluorescence sandwich immunoassay capable 5 
of quantifying E. coli in buffer and synthetic urine in less than 25 minutes without sample 6 
preparation nor concentration. A limit of detection (LoD) up to 240 CFU/mL, comensurate 7 
with cut-off for UTIs (103-105 CFUs/mL) was achieved. Replicas of full response curves 8 
performed with 100-107 CFUs/mL of E. coli K12 in synthetic urine yielded recovery values in 9 
the range 80-120%, assay reproducibility below 30% and precision below 20%, therefore 10 
similar to high-performance automated immunoassays. The unrivalled LoD was mainly linked 11 
to the ‘open fluidics’ nature of the 10-bore microfluidic strips used that enabled passing a large 12 
volume of sample through the microcapillaries coated with capture antibody. The new 13 
smartphone based test has the potential of being as a rapid, point-of-care test for rule-in of E. 14 
coli infections that are responsible for around 80% of UTIs, helping to stop the over-15 
prescription of antibiotics and the monitoring of patients with other symptomatic 16 
communicable diseases caused by E. coli at global scale. 17 
 18 
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1. Introduction 1 
Urinary tract infections (UTIs) are among the most common bacterial infections and 2 
pose a significant healthcare burden with Escherichia coli (E. coli) being the most predominant 3 
pathogen in over 80% UTIs (Moreno et al., 2006; Olanrewaju et al., 2017). The differentiation 4 
of asymptomatic UTI is subjective and symptoms nonspecific, overlapping with numerous 5 
others leading to an overprescription of antibiotics by clinicians, which contributes to retracted 6 
and reoccurring UTI crisis and accelerates the pace of multi-drug resistant ‘superbug’ 7 
emergence (Center for disease Dynamics, 2015; Cho et al., 2015; Kokkinis et al., 2016). 8 
Currently, E. coli present concerning resistant levels to the last generation of antibiotics 9 
(O’Neill, 2015), however, the current point-of-care (POC) devices for bacterial detection 10 
struggle to quantify low limit of detection (LoD) with high sensitivity and specificity enable to 11 
early detection of such infections (Cho et al., 2015; O’Neill, 2015). There is therefore a gap in 12 
diagnostic tools to quantify directly E. coli in biological samples. Lateral flow assays based on 13 
colorimetric strips to detect presence of nitrite and microfluidic paper analytical devices 14 
(μPADs) are currently availabe for a quick screening of UTIs yet lack specificity and provide 15 
non-quantitative information. 16 
Diagnosis of UTIs currently relies on clinical sample culture in a centralized laboratory 17 
facility, the total procedure requires a minimum of 2-3 days which limits the use of such 18 
phenotypic microbiological tests for rapid POC testing (Mairhofer et al., 2009; Olanrewaju et 19 
al., 2017). According to the european urinalysis guidelines, the limits for symptomatic UTI 20 
from midstream urine caused by E. coli is 103 CFU/mL (Aspevall et al., 2001; Schmiemann et 21 
al., 2010 ). This is intrinsically difficult to achieve with a conventional ‘dip stick’ test, mostly 22 
due to the very small sample volumes used. Bacterial detection can combine other detection 23 
principles such as biochemical staining and microscopy (e.g. Tallury et al., 2010; Zourob et al., 24 
2008), other biochemical tests identifying specific metabolites or enzymes (e.g. Tallury et al., 25 
2010; Zourob et al., 2008), immunoassays  including ELISA (e.g. Kokkinis et al., 2016; Phan 26 
et al., 2018; Su et al., 2015; Tallury et al., 2010; Zourob et al., 2008)) or molecular diagnostics 27 
such as PCR (e.g. Chang et al., 2015; Eltzov and Marks, 2016; Kailasa et al., 2019; Tallury et 28 
al., 2010; Zourob et al., 2008). These methods are very well understood and widely accepted 29 
for pathogen detection, however present long processing times and require expensive 30 
laboratory equipment and highly trained users, which is costly and not affordable by all 31 
healthcare systems. In addition most of the methods mentioned require several and lengthy 32 




and simple approaches to bacteria identification, ideally embedding affordable readout, simple 1 
fluid handling and on-chip reagents storage, suited to modern POC diagnostics 2 
commercialisation at a global scale (Mabey et al., 2004; Whitesides, 2006).  3 
The prevention and early identification of bacterial infections offers the potential for 4 
new cost-effective, sensitive, specific and rapid devices to tackle antimicrobial resistance 5 
(AMR). Microfluidic devices can brige the gap between empirical bacteria detection and high 6 
precision laboratory equipment by offering integration of multiple steps in one-step assay with 7 
portability, sample and reagent volume reduction, increased automation, lower power 8 
consumption and higher throughput (Barbosa et al., 2015; Gervais and Delamarche, 2009; 9 
Safavieh et al., 2014). There are many successful examples of application of microfluidic 10 
devices to several fields such as chemical synthesis, bioanalyticals, protein crystallization and 11 
POC diagnostics (Mabey et al., 2004; Whitesides, 2006). In spite of its well known avantages,  12 
miniaturisation also presents drawbacks, such as high manufacturing costs and reduced optical 13 
signal demanding sophisticated readout systems (O’Neill, 2016, 2015). These can involve 14 
absorbance, reflectance, fluorescence, surface plasmon resonance (SPR), bio-15 
chemiluminescence and electrochemiluminescence (Roda et al., 2016). The integration of 16 
smartphones with a cheap microfluidic device could however work as a cost-effective portable 17 
biosensor with tremendous potential for translating diagnostics from centralised labs to POC 18 
testing (Roda et al., 2016).  19 
The preferable readout approaches in microfluidic immunoassays are based in 20 
fluorescence and chemiluminescence due to their excellent sensitivity (Cox et al., 2012; 21 
Mairhofer et al., 2009). As an attempt to address the misdiagnosis of bacterial infections, some 22 
microfluidic platforms have been previously integrated with smartphones. For instance, 23 
Zeinhom et al. (2018) described a sandwich ELISA able to detect E. coli O157:H7 in 2h in 24 
yoghurt with a claimed detection limit of 1 CFU/mL and in egg with a claimed detection limit 25 
of 10 CFU/mL, however the assay in general presented a high backgound therefore a poor 26 
signal-to-noise (SNR) ratio. Cho et al., (2015) developed a bioassay based in a µPAD with a 27 
claimed detection of 1-103 CFU/mL of E. coli K12 and N. gonorrhoea diluted in urine, however 28 
this required several steps of sample preparation with 1% v/v Tween 80 and again the assays 29 
presented poor SNR. Rajendran et al. (2014) reported detection of 105 CFU/mL Salmonella 30 
spp. and E. coli O157 in PBS using biofunctionalized fluorescent nanoparticles. Zhu et al. 31 
(2012) published  a cell-phone platform with quantum dot enabled to detect 5-10 CFU/mL of 32 




reported on those studies, they all involved complex sample preparation or required extended 1 
assays times, both barriers to POC adoption of bacterial testing. 2 
In this study we present a sensitive and rapid optical sandwich fluorescent 3 
immunoassay able to detect and quantify E. coli K12 in less than 25 minutes in synthetic urine 4 
without the need of sample preparation, with the assistance of a smartphone camera. The new 5 
sandwich immunossay presents several advantages, such as: 1) affordable off-the-shelf 6 
immunoassay reagents, 2) rapid procedure (<25 min), independent on the doubling-time of 7 
bacteria, 3) no need for sample preparation and 4) inexpensive microfluidic strips based on an 8 
inexpensive, mass-manufacturable Microcapillary Film (MCF) fabricated from FEP-Teflon®, 9 
with excellent optical transparency, faciliting smartphone interrogation.  10 
 11 
2. Materials and methods 12 
2.1. Reagents and materials 13 
Unconjugated rabbit polyclonal antibody immunogen: O and K antigenic serotypes (all 14 
serotypes) of E. coli (#PA1-7213) was used as capture antibody (capAb) and the same antibody 15 
conjugated with biotin (#PA1-73031) as detection antibody (detAb), both from Fisher 16 
Scientific UK Ltd. LB Agar, Miller (#BP1425-2) and LB Broth, Miller (Granulated) 17 
(#BPE9723-2) used for microbiological culture, were purchased from Fisher UK. As blocking 18 
buffers we have tested the followings products: StartingBlockTM Buffer (#37538), Protein 19 
Free (TBS) & blocking Buffer (#37584) from Thermo Scientific (Northumberland, UK); 3% 20 
w/w Bovine Serum Albumin lyophilized powder, free of protein (BSA) (#A3858) from Sigma 21 
Aldrich (Dorset, UK) in 0.01M PBS; Elisa Synblock (#BUF034A) and Elisa Ultrablock 22 
(#BUF033A) were acquired from BioRad (Hertfordshire, UK); JSR Micro B-3001 and JLSP 23 
blocking buffers were donated by JSR Micro (Leuven, Belgium). SIGMAFASTTM OPD (o-24 
Phenylenediamine dihydrochloride) tablets (#P9187), Nunc maxisorp ELISA 96-well MTPs 25 
(#10547781), 0.01M at pH 7.4 Phosphate Buffer Solution (PBS) (#P5368) and synthetic urine 26 
(#S019) were sourced from Sigma Aldrich (Dorset, UK). High Sensitivity Streptavidin–HRP 27 
(#21130) were supplied by Thermo Scientific (Northumberland, UK). Enzyme and substrate 28 
for fluorescent immunoassay consisted of Alkaline Phosphatase (AP) enzyme substrate 29 
supplied by Cambridge Biociences (AnaSpec, # 71101-M) and AttoPhos(R) AP Fluorescent 30 
Substrate System (#S1000) purchased from Promega UK (Southamptom, UK). As washing 31 
buffers, 0.05% v/v Tween 20 diluted in 0.01M PBS (Sigma-Aldrich, Dorset, UK) and alkaline 32 




2.2. E. coli sample preparation 1 
A colony of E. coli K12 ‘’wild type’’ (NCIMB 11290) was picked up with a sterilized 2 
wire loop from a stock culture, inoculated in LB agar and incubated in a orbital shaking 3 
incubator under sterile conditions, at 37 ºC overnight. Afterwards the culture media was 4 
washed 3 times in PBS buffer using centrifugal separation and resuspended  in 0.01M PBS or 5 
synthetic urine, respectively. E. coli sample aliquots were prepared in 2 mL eppendorf with an 6 
OD600 of 0.7 and stored at -20 ºC. Serial dilutions were made from a volume of 0.1 mL E. coli 7 
samples in PBS and spreaded onto LB agar plates at 37 ºC overnight for estimating the cells 8 
present in fresh media. Positive and negative control plates with 0.01M PBS and agar without 9 
E. coli were performed to assess any contamination at this stage.  10 
2.3. MicroCapillary Film (MCF) strips 11 
We used cheap microfluidic strips manufactured from a 10-bore MCF (Figure 1A) 12 
using a novel melt-extrusion process by Lamina Dielectrics Ltd. (Billinghurst, West Sussex, 13 
UK) from fluorinated ethylene propylene co-polymer FEP-Teflon®. The MCF material used 14 
in this study presented an internal diameter of around 200 μm, with a small 5-6% variability 15 
linked to the design of the die and operational conditions used during the continuous  16 
manufacturing process (Edwards et al., 2011). MCF presents a high transparency ideal for 17 
sensitive optical detection by colorimetric or fluorescence assay and an hydrophobic internal 18 
surface that allows simple surface coating of capAb by passive adsorption. Based on the current 19 
cost of pelleted FEP of around £20/kg, the material cost for a 40 mm long strip (weighting 20 
around 0.2 grams) is neglegible. Due to the large surface-to-volume-ratio compared to 21 
conventional microwell ELISA platforms and its ‘open microfludic’ approach (enabling the 22 
use of a large volume of sample), high sensitivity is readily achieved.  23 
2.4. Fluorescent E. coli sandwich immunoassay  24 
Each reagent was manually aspirated with a 1 mL syringe connected to a MCF strip 25 
with a short (10-20 mm) piece of 3 mm i.d. silicon tube. Then, unconjugated polyclonal capture 26 
antibody (all serotypes) in PBS 0.01M at a concentration of 40 μg/mL was aspirated through a 27 
200 cm long MCF strip and incubated for 2h at room temperature in a sealed petri dish, to avoid 28 
evaporation, followed by  2 mL of protein free (TBS) blocking buffer for another 2h at room 29 
temperature. The MCF strip was then washed with 0.05% Tween-20 in PBS and trimmed into 30 
small 40 mm long strips. The initial stages of optimisation of the immunoassay performance 31 




Barbosa et al. (2014), extensively adapted to the detection of several biomarkers in the MCF 1 
platform (Barbosa et al., 2015; Castanheira et al., 2000). The procedure is further detailed in 2 
Supplementary Information. In brief, fluid flow in the MSA is driven by an array of 1 mL 3 
plastic syringes. In this study we noticed an advantage in using larger volumes of reagents 4 
and/or sample in respect to bacteria capturing and detection, consequently optimised 5 
immunoassays were carried out using manual syringes using procedure summarised in Figure 6 
1B. Optimised volumes and incubation times for both MSA and the manual syringe (MS) 7 
procedures are detailed in Table 1. For full response curves, a serial dilution of E. coli K12 8 
range from 108 to 100 CFU/mL in 3% w/w BSA or synthetic urine were loaded into a Nunc 9 
maxisorp microplate 400 μL well and 3% w/w BSA used as negative control. The MCF strip 10 
was then moved to a new well loaded with 40 μg/mL biotinylated polyclonal detection antibody 11 
(detAb) and washed with 0.05% w/w Tween 20 in 0.1M PBS (Figure 1B). Finaly, each strip 12 
was incubated with 4 μg/mL of alkaline phosphatase diluted in Tris-Buffered saline (TBS) at 13 
pH 7 before being washed three times with buffer (AnaSpec). Finaly, AttoPhos® AP 14 
fluorescent was aspirated for yielding an enzymatic fluorescence signal as illustrated in Figure 15 
1C.  16 
2.5. Signal quantification and image analysis 17 
Fluorescence MCF strips were imaged with a BioSpectrum 810 UVP System 18 
(AnalytikJena, Cambridge, UK) equipped with a deep-colled CCD camera using 2 seconds  of 19 
exposure time. Full response curve in synthetic urine were performed by imaging strips with a 20 
smartphone, as shown in Figure 2A. A Super bright 9 LED powered by 3 AAA torch (sourced 21 
from Mapplin, UK) was used for excitating the fluorophor and integrated in a black box 22 
manufactured in-house. The background signal for fluorescence emission was minimized using 23 
a 50 mm square dichroic additive amber filter sourced from Analytik Jena AG (Jena, 24 
Germany), place between the MCF strip and the smartphone camera to remove regions of the 25 
light spectrum below 430 nm. For smartphone imaging of fluorescence strips, we used a 60x 26 
magnification lens with a iPhone 6S attachment sourced from Amazon (Slough, Berkshire). 27 
Our simple setup enabled imaging the strips in dark conditions with low fluorescence 28 
background and good SNR (Figure 2B). RGB pictures collected with the smartphone’s camera 29 
were analysed with ImageJ software (NIH, USA) and we noticed the green channel provided 30 
maximum SNR (Figure 2B i). 31 
Fluorescence intensity (FI) was calculated from the greyscale pixel intensity, Iint for 32 




shown in Figure 2B ii). To minimize the intrisic variability from the smartphone camera 1 
settings, Iint was normalized by the mean intensity peak of reference strip Iint,ref  or by the 2 
exposure time of camera (which is recorded in the properties of the image file). Fluorescence 3 
immunoassay data was presented as fluorescence intensity ratio (FR) is given by the equation 4 




                           (1) 6 
AttoPhos® substrate was converted by alkaline phosphatase resulting in an 7 
enhancement in fluorescence signal. This is due to increased quantum efficiency, fluorescence 8 
excitation and emission spectra that are shifted well into the visible region, according to the 9 
manufacturer. We seelcted AttoPhos® as it presents an unusual large Stokes’ shift of 120 nm, 10 
which leads to lower levels of background fluorescence and higher detection sensitivity 11 
according to the supplier (Promega). FI values were normalized by dividing it with the 12 




                   (2) 14 
All immunoassay response curves were fitted with a theorethical 4 parameter logistic model 15 
(4PL) and the LoD determined as the minimum concentration yielding as negative control plus 16 
3 times the standard deviation of the blank. Separately, we have considered the impact of SNR 17 
(some literature suggests LoD is set by a SNR of 3) on LoD as the former impacts the signal 18 
strength and signal stability.  By analogy, the limit of quantification (LoQ) was calculated as 19 
the lowest concentrations of analyte (blank) plus 10 times the standard deviation (Barbosa and 20 
Reis, 2017; Shrivastava and Gupta, 2011). 21 
2.6. Robustness and reproducibility 22 
Robustness and reproducibility of the immunoassay were determined by replicating the 23 
same assay in different days. Results translated in terms of inter- and intra-assay variability. 24 
The measure of variability of the signal in a give same sample is termed precision and was 25 
expressed by the coefficient of variation (CV), obtained from the ratio of the standard deviation 26 
to the mean signal. When evaluated on the same assay run this is termed intra-assay variability, 27 
wherease different runs lead to inter-assay variability.  28 
In order to evaluate these parameters, three full independent replicates of smartphone 29 




different aliquots spiked with the same initial concentration of bacteria. Percentage recovery 1 
was calculated based on the ratio of fluorescence intensity (FI) by Equation (2) in 3% w/w 2 
BSA to the FI signal in synthetic urine sample.  3 
3. Results and discussion 4 
3.1. Development of colourimetric sandwich immunoassay 5 
In this study we have followed an immunossay detection approach to the quantitation 6 
of bacteria in a liquid sample, using E. coli as working model, a pathogen responsible for 7 
around 80% of UTIs. Due to the considerable size of bacteria (between 0.5 and 5 µm) (Foudeh 8 
et al., 2012), a sandwich immunoassay has the additional advantage over small protein 9 
quantitation of enabling the use of a single antibody for both detection and labelling of captured 10 
E. coli cells, by simply varying the conjugation with biotin or other molecule according with 11 
the fluorescent or colorimetric signal (Foudeh et al., 2012; Stratz et al., 2014; Wu et al., 2015). 12 
There are at least two major drawbacks identified with immunoassay detection of bacteria that 13 
explain the very limited success in development of rapid immunoassay tests for bacteria 14 
detection. Firstly, bacteria cells display different morphologies with many surface epitopes 15 
(proteins, glycoproteins, lipopolysaccharides, and peptidoglycan) that can lead to nonspecific 16 
signal interaction with the sensor surface (Ahmed et al., 2014). Secondly, the washing steps 17 
essentials for separating removing unbound detAb and enzyme and reducing the background 18 
(which sets the LoD) add shear which potentially displaces the captured bacterial cells from 19 
the capAb. We have addressed both issues by developing an immunoassay with polyclonal 20 
antibodies, which offers the possibility to capturing several O and K  E. coli serotypes 21 
responsible for UTI’s and developing multiplexing assays for other related bacteria causing 22 
UTI (e.g. Klebsiella and enterobactereace). In addition, we minimized the potential bacteria 23 
displacement caused by shear by incubating detection antibody after the bacterial sample. The  24 
sandwich ELISA configuration offers robustness resulting from the capture antibody-bacteria-25 
detection antibody complex (Deshpande, 1996). 26 
We noticed that the optimised conditions for the colourimetric E. coli sandwich 27 
immunoassay (summarised in Table S1 and further detailed in Supplementary Information 28 
document) were similar to those reported previously for protein biomarkers quantitation in the 29 
same microfluidic platform (Barbosa et al., 2015, 2014; Gervais and Delamarche, 2009). In 30 
particular, the immunoassay was very sensitive to the concentration of 40 µg/mL capAb 31 
(Figure S1) and incubation time of detAb, with little effect of enzyme complex. Also, protein-32 




for immunoassay reagents (Figure S2B). The immunoassay works with a polyclonal antibody 1 
that has the advantage of being strain-specific for few E. coli O- and K- serotypes with higher 2 
affinity according to supplier informations. Using the microengineering MCF material with 3 
multiple bores, we performed 10-replicas on each strip, however it would be possible to coat 4 
each capillary with a different capAb and hence use this system to detect a range of bacterial 5 
strains within a single assay. We noted similar concentrations of detAb and capAb (40 µg/mL) 6 
was paramount to achieving the best performance and 4 µg/mL the best concentration for HSS 7 
in colorimetric immunoassay (Figures S2C and S2D). Figure S3A showed a higher SNR was 8 
obtained with assay setting 3, consisting of consecutive incubations of the sample (3 min each) 9 
followed by 3 min incubation of detAb, a washing step, enzyme complex incubated for 4 min 10 
and finally 3 consecutive washings, before addition of Atthophos. 11 
3.2. Development of fluorescence sandwich immunoassay and effect of sample volume  12 
Initial trials with the optimised colourimetric immunoassay summarised in section 3.1 13 
showed very modest performance, with a LoD in the range of 105-106 CFU/mL (so well above 14 
the 103-105 CFU/mL required for diagnosis of UTIs) and few reproducibility issues. 15 
Consequentely, we have adapted the immunoassay to fluorescence quantitation with alkaline 16 
phosphatase; we kept the same concentration for enzyme complex (4 µg/mL) and AttoPhos®. 17 
Fluorescence immunoassays are widely recognized to present improved LoD in comparison to 18 
colorimetric assays (Barbosa et al., 2015; Zeinhom et al., 2018). We noticed a 1,000 fold 19 
improvement on the LoD (by reducing the LoD above stated for colourimetric assay 105-106 20 
CFU/mL to a LoD of 136 x 103 CFU/mL in fluorescence assay as shown in Table 2), however 21 
reproducibility remained inadequate, presumably due to the high variability in capturing E. coli 22 
cells which is very dependent of gravity and concentration as we reported recently in Alves 23 
and Reis (2019). 24 
We noticed the open microfluidic approach of the MCF strips are uniquely suited to 25 
passing a large volume of sample through the microcapillaries coated with capAb. Also, the 26 
surface-area-to-volume ratio in a 200 μm internal diameter capillary is about 16 times larger 27 
than on a 96 well microtiter plate filled with 100 μl of solution, favouring in-flow bacteria 28 
capturing through the formation of complex capAb-bacteria-detAb complex. We noticed 29 
fluorescence signal was remarkably improved by incubating the sample multiple times (Figure 30 
3A) during a fixed period instead of a single, longer incubation step (Figure S3). Figure 3B 31 
shows full response curves based on multiple steps of sample incubation, this strategy can be 32 




an improvement in 1-2 orders of magnitude in the LoD by carrying out the full assay with 1 
manual syringes instead of the MSA device, we believe this is mostly linked to the ability of 2 
using larger volume (4350l) of sample in manual syringes setup compared to MSA (with 3 
total reagents and sample volume limited to 1 mL) as summarised in Table 1. The full 4 
response curves shown in Figure 3B were obtained for a total of 19 min of assay plus 2 min for 5 
AttoPhos® conversion. The LoDs obtained for manual syringes and MSA were 510 CFU/mL 6 
and 1.3×104 CFU/mL, respectively. The assay variablity also remarkakly improved using 7 
manual syringes, with precision values in general remaining below 20% (Figure 3C). The SNR 8 
ratio also improved (Figure 3D), representing an effective increase on sensitivity as can be seen 9 
from the 1.5-fold increase on the slope. This effect is easily demonstrated in Figure S3B (in 10 
Supplementary Information) where the SNR from a single incubation of E. coli spiked in 3% 11 
BSA for 12 min was compared with 4 consecutive incubations of same bacterial sample by 3 12 
min each. A 3-fold increase in SNR was obtained for 103 CFU/mL with around 6-fold 13 
impovement noted for 106 CFU/mL, without any negative impact on non-specific (background) 14 
signal. 15 
Prior to the development of the rapid and sensitive E. coli immunoassay using a 16 
smartphone as a readout system, the validation of assay performance in synthetic urine 17 
involved fluorescence scanning of the strips with UVP’s gel imaging system. Experiments 18 
showed a sensitive performance of fluorescent E. coli quantification assay without any 19 
detrimental effect on background. Table 2 summarised all fluorescent assays carried out in less 20 
than 25 min and respective fitting to 4PL correlation, LoD and LoQ. The fluorescent 21 
immunoassay in synthetic urine showed 2.5-fold improvement in the LoD, with a LoD of 191 22 
CFU/mL and a LoQ of 575 CFU/mL with an R2 = 0.998, matching a high sensitivity of clinical 23 
threshold for an UTI caused by E. coli, when compared to non-optimised conditions. Very 24 
often, biological matrix effects can interfere in the equilibrium capAb-bacteria-binding. The 25 
need of no sample preparation presents multiple advantages in respect to the design of the 26 
device and speed of the testing. This remarkable finding can be explained by the surface-area-27 
to-volume-ratio of FEP microcapillary platform that is 4 times larger than any other surface in 28 
a microchannel with same internal dimensions. Therefore antibody–antigen binding is 29 
favoured by the increased concentration of free binding sites of capAb on the microcapillaries 30 
surface, which results in higher assay sensitivity (Castanheira et al., 2015). Neverthless 31 
sysnthetic urine presents a neutral acidic neutral pH (6-7) that favours antibody activity, 32 




3.3. Proof-of-principle of portable smartphone quantification of E. coli in synthetic urine 1 
As a first step, the optical detection of converted fluorescent substrate was studied in 2 
the smartphone setup and fluorescence calibration curve represented in Support information of 3 
this manuscript (Figure S4) The use of the correct environment, light source, angle and design 4 
all interfere with the accuracy and sensitivity of a smartphone’s camera to image fluorescent 5 
strips. A series of 1:2 dilutions of 1 mM of fully converted AttoPhos were loaded into eight 4 6 
cm MCF strips and placed individually into the smartphone setup seen in Figure 2A. At this 7 
stage it was determined that the best position of the super bright 9 LED torch was to hold this 8 
at the front of the house made dark polyethylene box, hence allowing the light to penetrate 9 
along the length of the channels rather than across them. This resulted in sharper images. The 10 
control of environmental light is often difficult, producing variability across multiple pictures, 11 
so a reference strip with converted AttoPhos was imaged at the same time of the experimental 12 
strip, enabling to reduce variability by normalizing the fluorescent signal. These normalized 13 
light conditions improved also the image quality capturing caused by variations in the exposure 14 
time of the camera (which is usually done automatically by software embedded in the 15 
smartphone). Figure 4 shows the results of smartphone fluorescent E. coli immunoassays in 16 
synthetic urine. Values of LoD and LoQ were described in Table 2, supporting the superior 17 
performance of fluorescent bacteria testing in microcapillaries, with a LoD of 240 CFU/mL 18 
and a LoQ of 1327 CFU/mL obtained in less than 25 min.  Although in line with current 19 
expectations for detection of UTI, we observed a slight reduction of 50 CFU/mL in LoD and 20 
572 CFU/mL of LoQ in comparison to imaging with the fluorescence gel scanner. 21 
Previous studies have reported microfluidic fluorescence assay for UTI diagnosis with 22 
particular focus to E. coli detection and quantitation in buffer, synthetic urine or urine but the 23 
assay times used were typically longer, requiring more sample preparation and unable to meet 24 
the levels of  LoD obtained our work. For example, Yoo et al. (2014) reported a LoD of 103 25 
CFU/mL of E. coli in PBS using a microfluidic fluorescence assay with total assay taking 30 26 
min plus 45 min for staining. Yang et al. (2011) reported an LoD of 3.4×104  CFU/mL of E. 27 
coli in synthetic urine with total assay taking 100 min. Safavieh et al. (2012) developed a 28 
microfluidic loop-mediated isothermal amplification (LAMP) with electrochemical detection 29 
presenting an LoD of 48 CFU/mL of E. coli involving sample preparation by filtration of urine 30 
and total assay time of 60 min.  31 
Robustness and reproducibility of the smartphone fluorescence immunoassay were 32 




and intra-assay variability as summarised in Figure 4C. The measure of the variability of the 1 
signal in the same sample (precision) is termed precision and expressed by the coefficient of 2 
variation (CV), which is obtained by the ratio of the average signal and the standard deviation. 3 
In general, the precision of the three independent assays remained below 20%, as shown in 4 
Figure 4C(i). SNR values presented in Figure 4C(ii) show a slight decrease (around 0.5-fold) 5 
when compared to the values achieved for assay in buffer (Figure 3B). This difference was 6 
mainly noticeable at the highest concentrations of E. coli when the fluorescent signal is 7 
proportionally stronger or saturated and harder to be quantified due to limitations with camera 8 
detection. Furthermore, intra-assay precision was also evaluated and displayed in Figure 4C(iv), 9 
in general it remained below 30%, being slightly higher at lower E. coli concentrations in 10 
synthetic urine. According to Wild (2013) this is still within an acceptable limit due to 11 
cumulative errors effecting the different steps. Recovery values for each concentration showed 12 
very linear and consistent within ranges 80-120% (Figure 4C(iii)), meeting the target for high-13 
performance immunoassays. This ultimately demonstrates the fluorescent E. coli immunoassay 14 
coupled with a smartphone is efficient for E. coli quantification in synthetic urine, without any 15 
steps of sample preparation. Future developments will be centralized in a new concept of 16 
reagents loading to minimize detrimental shear stress on capture of bacterial cells and boost 17 
robustness of this microbiological test and develop a portable light detector by developing 18 
simple accessories that create a compact dark box around the photo camera, preventing ambient 19 
light from interfering with the test’s light signal. 20 
4. Conclusions 21 
This work demonstrated proof-of-principle for a new affordable, optical microfluidic 22 
test integrated with a smartphone camera able to perform a fluorescence immunoassay 23 
quantitation of E. coli. Full response curves performed in both buffer and synthetic urine 24 
yielded a LoD of up to 240 CFU/mL in less than 25 minutes, which is compatible with clinical 25 
cutt-off for UTIs caused by E. coli. The ability to pass a large volume of sample through the 26 
‘open’ microfluidic strips was revealed as key to yielding >100-fold improvement on LoD. 27 
This is believed to be linked to increased number of bacterial cells captured by the immobilised 28 
capture antibody before addition of immunoassay reagents. The recovery and inter- and intra-29 
variability data demonstrated the bioassay is simple yet robust and reproducible, and 30 
comparable to high-performance protein immunoassays. Future work will report strategies for 31 
power-free reagents loading and improvement on smartphone fluorescence interrogation, and 32 




strategy for rapid identification of E. coli is relevant for fighting the current pace of antibiotic 1 
resistance caused by the current empirical prescription of antibiotics worldwide, particulary in 2 
low income countries where patients have limited access to centralised microbiology and 3 
pathology labs. Further studies using clinical samples and performing cross reactivity tests will 4 
be subject of future publications. 5 
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List of Tables 1 
 2 
Table 1 E. coli immunoassay steps, conditions and volume range 3 
Bacterial assay 









[109 - 101 ] 
CFU/mL 
150 × 4 350 × 4 
DetAb 
incubation 
3 40 μg/mL 150 250 
Washing - - 150μl 300 
Enzyme 
incubation 
4 4 μg/mL 150 250 




1-5 0.6 mg/mL 150 150 
Total assay time 20-25 min 




Table 2 Performance of fluorescence immunoassay determined from full response curves for 1 
a E. coli concentration of 100-107 CFUs/mL 2 
Sample Fluidics Imaging device 
(fluorescence) 
Data correlation 








Buffer MSA Gel scanner 
0.999 136×103 572×103 
< 25 
min 
Buffer MS Gel scanner 0.995 473 1300 
Synthetic 
urine 
MS Gel scanner 




0.996 240 1327 
 3 




Figure captions 1 
Figure 1 FEP-Teflon® microcapillaries platform represented in A and E. coli quantitative 2 
fluorescent immunoassay steps in B with final configuration of E. coli detection, after 3 
conversion of final fluorescent product in C. 4 
Figure 2 Smartphone components used for E. coli quantitative fluorescent immunoassay and 5 
signal image analysis A Smartphone set up and accessories to coupled E. coli fluorescence 6 
immunoassay (i) Super bright 9 LED torch, (ii) dichroic additive amber filter (iii) MCF support 7 
(iv) integrated magnified lens (v) smartphone (iPhone® 6S, 12 megapixels camera); B 8 
fluorescence signal quantitation (i) RGB and green channel image (with reference strip of 0.125 9 
mM Atthophos), (ii) correspondent grey scale analysis. 10 
Figure 3 Comparison of E. coli fluorescence immunoassay performance in buffer (3% BSA) 11 
using multi syringe aspirator and free range of volumes with single syringes. A Principle of 12 
affinity used in MCF coated to enhance sensitivity B Full response curves for a E. coli 13 
concentration of 100-107 CFUs/mL C Precision range achieved in all E. coli concentration 14 
tested D Signal-to-noise-ratio (SNR) comparison between assays. 15 
Figure 4 Smartphone fluorescence detection of E. coli in synthetic urine. A RGB and Green 16 
channel images of MCF phone quantitation, B Full response curve at 2 minutes of Atthophos 17 
conversion testing an E. coli concentration of 100-107 CFUs/mL, C Inter-variability study 18 
showing the precision range (i) and SNR overall (ii). Intra-variability study for a triplicate 19 
quantitation of E. coli in 3 different days showing the percentage of sample recovery in (iii) 20 
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